Integrin alpha4beta1 Inhibitors
2 drugsAbout Integrin alpha4beta1
Integrin alpha4beta1, or α4β1 integrin, is a cell surface receptor mediating cell adhesion and migration via interactions with the extracellular matrix. As a heterodimeric protein, it influences biological processes, making it a compelling drug target.
Integrin alpha4beta1 is a therapeutic target despite the lack of direct genetic evidence linking it to specific diseases. The existence of two FDA-approved drugs suggests the feasibility of modulating its activity for clinical benefit.
Two FDA-approved drugs target Integrin alpha4beta1: TYRUKO and TYSABRI, developed by Novartis and Biogen, respectively. These drugs include one antibody and one "biologic (other)" modality, used in CNS and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
- Emerging modalities (Antibody) signal innovation opportunity.
Top Integrin alpha4beta1 Drugs
Novartis and Biogen are the only two companies with approved drugs targeting Integrin alpha4beta1.
The limited number of players indicates a high barrier to entry or untapped market potential.
Integrin alpha4beta1 Drug Modality Landscape
Modalities
Routes of Administration
Integrin alpha4beta1 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Exploring small molecule inhibitors could offer a novel approach to targeting Integrin alpha4beta1.
📈 Modality Evolution
Antibodies pioneered Integrin alpha4beta1 targeting (2004), with other biologics entering more recently (2023).
Integrin alpha4beta1 Clinical Trials 35 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 3 | 2 | 0 | 60% |
| Phase 2 | 12 | 10 | 1 | 1 | 91% |
| Phase 3 | 4 | 1 | 3 | 0 | 25% |
| Phase 4 | 14 | 8 | 6 | 0 | 57% |
Top Sponsors
By Modality
Top Conditions
Integrin alpha4beta1 Drug Approval Timeline (2004 - 2023)
The first drug was approved in 2004, with the most recent in 2023, spanning 20 years.
The recent approval suggests renewed interest, but also a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 22 clinical trials targeting Integrin alpha4beta1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities